Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 38Pancreatic Neoplasms 16Colonic Neoplasms 12Rectal Neoplasms 11Stomach Neoplasms 9Neoplasms 9Neuroblastoma 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Neoplasm Metastasis 7Glioblastoma 7Sarcoma, Ewing 6Gastrointestinal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioma 5Sarcoma 4Brain Neoplasms 4Medulloblastoma 3Intestinal Neoplasms 3Gliosarcoma 3Gastrointestinal Diseases 3Esophageal Neoplasms 3Digestive System Neoplasms 3Digestive System Diseases 3Astrocytoma 3Advanced Solid Tumors 3Recurrence 2Rectal Diseases 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

Fluorouracil 2Cisplatin 2toripalimab 1spartalizumab 1pembrolizumab 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Injections 1Gemcitabine 1Drug Therapy 1Docetaxel 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Malignant Tumors × Irinotecan × Clear all
NCT05235542 2022-08-11

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Akeso

Phase 1/2 Unknown
130 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡